Novartis Restructure: With top names departing, refocused therapeutic priorities & new targets set, this @PharmaScrip article by @awmcconaghie is important reading for all in the industry, from biotech partners (and would-be partners) to big pharma peers. https://t.co/ZwokWkevMQ
Alexander Natz of @EUCOPE explains in this @PharmaPinkSheet article the new EU regulation on health technology assessment, one of the biggest developments to affect the pharma industry in over a decade. https://t.co/h31VR0HU1u
Welcome to #DIAEurope2022 !
#Day1 we are so excited to be face-to-face in Brussels!
Our three-day event is just beginning, there is still time to attend!
Click here to register today: https://t.co/6KMeqIkLTo
EMA’s Management Board elects Lorraine Nolan as its chair for a three-year mandate.
Dr Nolan is the Chief Executive of @TheHPRA.
👉https://t.co/qYlmS0RGvF
This first edition of Report Digest from @PharmaPinkSheet sister publication @Medtech_Insight covers the liquid biopsy for oncology market. The podcast considers the main market drivers and what might occur in the sector in future years. https://t.co/dbn12xAsS7
This free-to-view article from @PharmaPinkSheet sister publication @Genericbulletin highlights the off-patent industry's involvement in fighting the COVID-19 pandemic in 2021. https://t.co/XHhyMCPjdV
Digital therapeutics are expected to play an ever-bigger role in the treatment & management of diseases. @medtechMarion reports in this free @INVIVOnow article that this subcategory of the digital health solutions market could be worth $9bn by 2025. https://t.co/dNEIlxVAej
This free-to-view timeline from @PharmaPinkSheet is one of a three-part Drug Review Profile package comparing how @US_FDA and @EMA_News reviewed @JanssenGlobal's MS drug Ponvory. Our signature deep-dive DRPs are of interest to drug developers everywhere. https://t.co/fFun6ZnIpF
The @EMA_News is in overdrive on the coronavirus front. Read our @PharmaPinkSheet coverage of the latest developments, by @ScripIanS. https://t.co/nLz6E1Kmy9
We have just issued advice for 🇪🇺 countries who may decide on early use of the oral antiviral developed by Pfizer, before marketing authorisation.
In parallel, we started the #RollingReview for this #COVID19treatment.
👉 https://t.co/c8iqfTDYvq
"We need help." "Everybody is under severe pressure here." "We have [an] increasing number of staff on long-term sick leave." Frank talk from @EMA_News head Emer Cooke. #Covid#workload Read the full free-to-view article by @PharmaPinkSheet's @ScripIanS: https://t.co/R1B1WazrDT
Plenary 3: @runnerosborn of @pfizer discusses innovation of medicines and vaccines have never been more exciting, seeing a real increase in volume and speed coming through pipeline, specifically for personalized medicine treatment. #ISPOREurope
Moderna’s Phase III COVE study of mRNA-1273 for COVID-19 prevention has also won the category for Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award – Sponsored by Parexel – well done!
#ScripAwards
Congratulation to both BenevolentAI and AstraZeneca for AI and machine learning to discover potential new treatments for chronic kidney disease and idiopathic pulmonary fibrosis and are taking home the trophy for Best Partnership Alliance #ScripAwards
The winners of the Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award – Sponsored by Parexel are CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) – congratulations! #ScripAwards
The Award for Best New Drug Award - non COVID-19 has been awarded to GlaxoSmithKline’s Blenrep (belantamab mafodotin) for multiple myeloma
#ScripAwards
The Clinical Advance of the Year Award is Sponsored by Parexel and the winner is Takeda Pharmaceutical Company's Phase III SOLSTICE trial of maribavir in transplant recipients with CMV infection #ScripAwards